Related Experiment Videos
IgD myeloma: a potential missed diagnosis
1Department of Chemical Pathology, Queen Alexandra Hospital, Portsmouth, UK. davidsinclair@QMAIL01.porthosp-swest.nhs.uk
Annals of Clinical Biochemistry
|October 6, 2001
Summary
IgD lambda myeloma can be missed if not specifically investigated. This case highlights the importance of evaluating serum and urine for all suspected myeloma cases, especially those appearing as free light chain paraproteins.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Multiple myeloma is a plasma cell malignancy.
- Diagnosis often relies on detecting monoclonal proteins (paraproteins) in serum or urine.
- IgD myeloma is a rare subtype, posing diagnostic challenges.
Observation:
- A suspicious 'low gamma region' in serum protein electrophoresis prompted further investigation.
- Initial findings suggested Bence Jones myeloma (light chains only).
- Specific anti-IgD testing revealed the presence of IgD lambda paraprotein.
Findings:
- The case was diagnosed as IgD lambda myeloma.
- Failure to perform anti-IgD investigations could lead to misdiagnosis as Bence Jones myeloma.
- Comprehensive evaluation of both serum and urine is crucial for accurate myeloma diagnosis.
Implications:
- This case underscores the necessity of investigating IgD myeloma, particularly when only free light chains are detected.
- Routine evaluation of serum and urine is mandatory in suspected myeloma cases.
- Early and accurate diagnosis of rare myeloma subtypes like IgD myeloma is vital for appropriate patient management.